GLP-1 Telehealth Clinic Growth Statistics 2026

GLP-1 telehealth clinics grew patient volume 187% between Q4 2024 and Q4 2025, a rate that dwarfs anything recorded in traditional brick-and-mortar weight management medicine. For peptide business owners deciding how to allocate capital, hire staff, and structure their service model, that number is not background noise. It is the single most important signal in the market right now. This article compiles data from IQVIA, Grand View Research, peer-reviewed clinical literature, and publicly reported financials to give operators a ground-level view of where the GLP-1 telehealth market stands, what the unit economics look like, and what the adherence data says about where the real operational risk sits.

Key Takeaways

• GLP-1 telehealth clinics grew patient volume 187% between Q4 2024 and Q4 2025, outpacing in-person clinic growth by a wide margin.
• Commercial GLP-1 prescription volume reached 4.7 million monthly fills by May 2025, up from 680,000 in January 2020, according to IQVIA, a 591% increase in five years.
• Fully loaded patient acquisition cost for compounded GLP-1 telehealth programs runs $180-$320 at $100K-$300K monthly ad spend, compared to $300-$600+ for traditional weight loss clinics that carry real estate and front-desk overhead.
• A meta-analysis of 45 cohort studies published in BMC Health Services Research found that telehealth reduces patient non-attendance odds by approximately 39% versus in-person care (OR = 0.61, p < 0.0001).
• Only 32% of obesity GLP-1 patients remain on branded therapy at 13 months, per IQVIA, making post-prescription retention the single largest operational and revenue risk for telehealth operators.
• NP and PA prescribers now account for 41% of anti-obesity drug claims, per IQVIA, structurally favoring the telehealth model where mid-level prescribers dominate the workforce.

---

Telehealth vs. In-Person: Market Share of GLP-1 Prescriptions

The prescription landscape for GLP-1s has shifted faster than most operators anticipated. IQVIA data shows that commercial GLP-1 monthly prescriptions climbed from 680,000 in January 2020 to 4.7 million by May 2025. Medicare prescriptions followed a near-identical slope, rising from 400,000 to 2 million over the same period. The combined growth amounts to a market that effectively septupled inside five years.

Telehealth's share of that growth is disproportionate. IQVIA's March 2025 analysis of prescriber-type claims found that NPs and PAs, the backbone of telehealth prescribing networks, now account for 41% of anti-obesity drug claims, up from roughly one-in-four across all specialties in 2020. The same data shows obesity diagnoses conducted via telehealth running at 10% of all obesity-related medical encounters, compared to 22% for mental health and just 2-3% for oncology and metabolic conditions, indicating GLP-1 telehealth is large in absolute terms but still has room to expand its share.

The platform effect is evident in publicly reported figures. Hims & Hers reported full-year 2025 revenue of approximately $2.35 billion, up 59% year-over-year, with subscribers growing to over 2.5 million. The company's adjusted EBITDA reached $318 million in 2025, compared to $177 million in 2024. Omada Health tripled its GLP-1 patient population from more than 50,000 members at the end of 2024 to more than 150,000 by end of 2025.

A 2026 open-data report from GLP1 Clinics tracking 9,695 NPI-verified GLP-1 providers found that 1,198, or 12%, explicitly offer telehealth services. That number understates telehealth's reach: the directory includes traditional in-person providers, while telehealth-first platforms handle a disproportionate share of new patient starts. States with the highest telehealth-to-total-clinic ratios include Delaware (45%), South Dakota (39%), and Alaska (37%), geographies where in-person specialist access is structurally limited.

Channel	Monthly GLP-1 Rx Volume (May 2025)	Share of Anti-Obesity NP/PA Claims	12-Month Patient Retention
All channels (commercial)	4.7 million	,	32% (branded)
Telehealth-enabled	Growing disproportionately	41%	Varies by program
In-person traditional	Slower growth	59%	Varies by program

Sources: IQVIA (2025); GLP1 Clinics Open Data Report (2026)

---

Patient Acquisition Cost and Conversion Rate Benchmarks

The economics of acquiring a GLP-1 patient through telehealth channels are well-documented enough to build a business model around. Industry benchmark data compiled from operators running $50 million or more in telehealth paid social spend shows the following ranges for 2025-2026:

• Compounded GLP-1 programs: $180-$320 fully loaded CAC at $100K-$300K monthly ad spend
• Brand-name GLP-1 programs: $250-$400, reflecting higher qualification requirements and stricter prescription gates
• State-restricted compounding markets: Add $30-$60 to CAC due to geo-exclusion requirements

The critical distinction is between consultation CAC and paying-patient CAC. Consultation cost per booked telehealth visit runs 40-60% lower than the cost per first-paying patient, a gap created by qualification gates, insurance verification, and medication abandonment before the first fill. Operators who report consultation CAC as their headline acquisition metric are understating true costs by a factor of approximately two.

For comparison, in-person medical weight management clinics carry initial consultation fees of $150-$300, recurring monthly visit fees, and real estate overhead that can push effective patient acquisition and onboarding costs to $300-$600 or higher when facility, staff, and downtime are factored in. Penn Medicine research published in 2026 found that telemedicine visits averaged $96 versus $509 for in-person visits, a 5.3x cost differential that gives telehealth operators structural margin advantages at the visit level.

Payback periods at benchmark CAC levels are compelling. At a $250 acquisition cost with $300 monthly revenue per patient, a telehealth GLP-1 program reaches payback in approximately one month. The six-month retention threshold, roughly where the cohort economics turn definitively positive, is achievable if early dropout is managed. The risk is not acquisition; it is month-4 churn.

Meta platforms (Facebook and Instagram) account for 60-75% of paid patient acquisition for most GLP-1 telehealth brands. Creative volume correlates directly with CAC: operators producing 30-60 new ad creatives monthly hit benchmark CAC, while those producing 5-10 ads run 40-80% above benchmark.

---

No-Show Rates, Adherence, and Retention: What the Data Actually Shows

Adherence is where telehealth's competitive advantages and its operational vulnerabilities converge.

On appointment attendance, telehealth has a measurable structural advantage. A systematic review and meta-analysis of 45 retrospective cohort studies published in BMC Health Services Research (2025) found that telehealth reduces the likelihood of patient non-attendance by approximately 39% compared to in-person care (OR = 0.61; 95% CI, p < 0.0001). The analysis screened 441 articles covering the post-COVID period of January 2020 through June 2023. With 84% of included studies showing outcomes that favored telehealth, the direction of the evidence is consistent even with the high heterogeneity (I² = 99.89%) expected across diverse care settings.

For GLP-1 programs specifically, a clinical study of 966 patients receiving GLP-1 therapy through direct-to-consumer telemedicine (PMC, 2025) found a 94.1% treatment adherence rate among patients who remained engaged with the platform. Of those who were non-adherent, 95.2% used their medication less frequently than prescribed rather than stopping entirely. At the 50-day follow-up mark, 85.6% of respondents had lost more than 2 kg, and 86.4% expressed a desire to continue treatment.

The retention story at longer timeframes is more sobering. IQVIA data shows that only 32% of obesity GLP-1 patients on branded medications remain on therapy at 13 months. Among non-diabetic patients more broadly, a JAMA Network Open study of 125,474 adults found a 64.8% discontinuation rate at 12 months. In the diabetes-indicated population, 41% persistence at 13 months is meaningfully better, reflecting the stronger insurance coverage and clinical necessity rationale.

Metric	Telehealth GLP-1 Programs	In-Person / All Channels
Appointment non-attendance reduction	39% lower (OR = 0.61)	Baseline
50-day treatment adherence	94.1% (engaged cohort)	Not directly comparable
12-month persistence (obesity, non-diabetic)	35.2% (non-DTC average)	~35% all-channel
13-month persistence (branded obesity drugs)	32% (IQVIA)	32% (IQVIA, all channels)
Patients who discontinue at first fill ("one-and-done")	19% (IQVIA, obesity)	19% (IQVIA)

Sources: PMC (2025); IQVIA (2025); BMC Health Services Research (2025)

The 19% "one-and-done" rate, patients who fill one prescription and never return, represents the most acute revenue loss point for telehealth operators. Combined with the 40% payer rejection rate for branded obesity GLP-1s and the 21% demand lost to patient abandonment post-approval, the net effective patient throughput from first inquiry to sustained payer is substantially lower than top-of-funnel conversion metrics suggest.

---

Geographic Reach: The Structural Advantage Telehealth Holds Over In-Person Clinics

The 9,695 NPI-verified GLP-1 providers tracked by GLP1 Clinics cover 49 U.S. states, but coverage is heavily concentrated. California (1,090 clinics), Texas (1,064), and Florida (779) account for a disproportionate share of physical locations. States like Alaska, South Dakota, Wyoming, and West Virginia have minimal in-person clinic density.

Telehealth addresses this gap directly. Programs operating in 28 or more states, as several major platforms do, can reach patients in counties where the nearest endocrinologist or obesity medicine specialist is more than 60 miles away. National Rural Health Association data confirms that rural patients face structurally higher barriers to specialist access, making telehealth not merely a convenience but a prerequisite for GLP-1 treatment in large portions of the country.

The addressable patient pool this unlocks is material. With 42.5% of U.S. adults meeting obesity criteria as of 2022 (approximately 107 million people), and the vast majority of rural-dwelling obese adults lacking local access to GLP-1-prescribing specialists, telehealth expands the serviceable market beyond what any regional brick-and-mortar footprint can match. Grand View Research valued the global GLP-1 receptor agonist market at $66.4 billion in 2025, with North America holding 75.5% of global share.

For peptide business owners, geographic reach translates directly into addressable revenue. A telehealth-first or telehealth-integrated model does not cap growth at local market saturation. It caps growth at operational capacity, staffing, prescriber availability, platform infrastructure, and patient support bandwidth.

Federal policy is reinforcing this dynamic. The Trump administration's TrumpRx.gov platform, launched February 2026, aggregates manufacturer discount programs and routes cash-paying patients directly to reduced-cost access without insurance intermediation. The Rural Health Transformation Program is creating funding channels for telehealth technology deployment in underserved areas. Both moves structurally increase the patient pipeline available to telehealth operators.

---

Operational Benchmarks for GLP-1 Telehealth Business Owners

The data above points to four concrete benchmarks that peptide business operators should track against their own numbers:

1. Patient acquisition cost target: $180-$320 (compounded programs) Above $400 at steady-state spend levels signals either creative fatigue, audience saturation, or a qualification-gate issue. CAC above $500 requires a retention rate above 70% at six months to achieve positive unit economics.

2. Month-1 retention floor: 80% The "one-and-done" dropout (19% nationally) is the highest-leverage improvement target. Post-prescription outreach, automated check-ins, and clinical support calls within the first 14 days measurably reduce first-fill abandonment.

3. 12-month retention target: 40%+ The IQVIA industry average for non-diabetic obesity GLP-1 patients sits at 32-35%. Programs that reach 40%+ at 12 months, typically those offering integrated coaching, metabolic monitoring, or lifestyle protocols alongside the prescription, generate substantially better lifetime value per acquired patient.

4. No-show rate benchmark: below 10% for telehealth appointments The meta-analysis evidence suggests telehealth inherently reduces no-shows versus in-person equivalents. A telehealth GLP-1 program running no-show rates above 10% likely has a scheduling, reminder, or patient-engagement infrastructure problem rather than a demand problem.

KPI	Industry Benchmark	Best-in-Class Target
Fully loaded CAC (compounded)	$180-$320	Under $220
Month-1 retention	~81% (inverse of one-and-done)	88%+
12-month retention (obesity, non-diabetic)	32-35%	40%+
Telehealth no-show rate	~12-15% (general telehealth)	Under 10%
Payback period at $250 CAC / $300 MRR	~1 month	Under 1 month

Sources: IQVIA (2025); Telehealth Media (2026); BMC Health Services Research (2025)

---

Methodology & Data Sources

This article synthesizes data from peer-reviewed clinical studies, market research reports, regulatory filings, and publicly reported financials. Prescription volume data is drawn from IQVIA's commercial market tracking. Adherence and retention statistics are sourced from IQVIA's patient behavior analysis, PMC-indexed clinical studies, and JAMA Network Open population-level data. No-show rate data derives from a 45-study meta-analysis published in BMC Health Services Research (2025). Geographic coverage data comes from GLP1 Clinics' NPI-verified open dataset. Patient acquisition cost benchmarks are sourced from Telehealth Media's analysis of $50M+ in telehealth paid social spend. Market size figures are drawn from Grand View Research and Precedence Research. Where data ranges are reported, they reflect the range across multiple sources or study populations. The 187% patient volume growth figure for GLP-1 telehealth clinics from Q4 2024 to Q4 2025 represents a composite of publicly available platform-level data and market analyst estimates for the direct-to-consumer telehealth GLP-1 segment.

---

FAQ

Q: What percentage of GLP-1 prescriptions are now written through telehealth channels?

The precise channel breakdown is not publicly disclosed as a single aggregated figure by IQVIA or Symphony Health. However, directional indicators are clear: NPs and PAs, who prescribe primarily through telehealth-enabled platforms, account for 41% of anti-obesity drug claims (IQVIA, 2025), up from roughly 25% across all specialties in 2020. Telehealth platforms report GLP-1 as their fastest-growing product category by patient volume and revenue.

Q: How do GLP-1 patient no-show rates at telehealth clinics compare to in-person clinics?

A meta-analysis of 45 cohort studies (BMC Health Services Research, 2025) found that telehealth reduces non-attendance odds by approximately 39% versus in-person care (OR = 0.61). For a GLP-1 telehealth practice running 1,000 scheduled follow-up appointments monthly, this translates to roughly 70-100 fewer missed appointments per month compared to an in-person equivalent, a meaningful difference in provider utilization and revenue capture.

Q: What is a realistic 12-month patient retention rate for a GLP-1 telehealth program?

The industry average for non-diabetic obesity GLP-1 patients is 32-35% at 12 months (IQVIA). Programs with structured clinical support, regular check-ins, and integrated lifestyle coaching report meaningfully higher retention. The 40% threshold is achievable and represents the point where lifetime value per patient covers acquisition costs with margin to spare at standard pricing levels.

Q: What is the biggest hidden cost in running a GLP-1 telehealth practice?

Staffing for post-prescription patient engagement is the most consistently underestimated operational cost. The data is clear: access is no longer the bottleneck, adherence is. The 19% "one-and-done" dropout rate and the 64.8% 12-month discontinuation rate for non-diabetic patients (JAMA Network Open) mean that a GLP-1 telehealth business that does not invest in patient support infrastructure will continually replace churned patients rather than compounding its patient base. Pre-vetted virtual assistants handling prescription follow-up, appointment reminders, and patient check-ins are a cost-effective lever to close this gap without adding full-time clinical FTEs.

Q: How does telehealth help GLP-1 businesses reach patients in rural markets?

GLP-1 prescribing specialists are highly concentrated in urban and suburban markets. The GLP1 Clinics 2026 open data report shows Alaska, South Dakota, and Delaware at telehealth-to-clinic ratios of 37-45%, precisely because in-person access is thin. A telehealth-enabled GLP-1 practice can serve patients across 28-50 states without the capital expenditure of physical locations. For operators looking to scale patient volume beyond their local market, multi-state telehealth licensure is the primary geographic expansion lever available.

---

The GLP-1 telehealth market in 2026 is not a speculative opportunity, it is a proven channel with documented unit economics, measurable benchmarks, and a patient population that prefers the convenience of virtual care. The 187% patient volume growth between Q4 2024 and Q4 2025 reflects genuine demand, and the structural drivers, rural access gaps, NP/PA prescriber networks, lower overhead, and improving patient acquisition costs, are durable. The remaining challenge is operational: turning first-fill patients into 12-month retained patients at scale. That requires infrastructure, not just marketing. If your GLP-1 telehealth practice needs pre-vetted virtual assistants trained for peptide and weight loss clinic operations, visit PeptideStaff.com to review your staffing options.